FIELD: biotechnology.
SUBSTANCE: invention relates to the methods of introducing genetically modified B cells to ensure the production of a therapeutic agent, such as a therapeutic protein, by administering a single maximum effective dose of genetically modified B cells.
EFFECT: invention is applicable for long-term delivery of a therapeutic agent in vivo.
9 cl, 2 tbl, 16 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF TREATING MPS1 | 2014 |
|
RU2708318C2 |
| ADENO-ASSOCIATED VIRUS VECTOR FOR THERAPEUTIC DELIVERY INTO THE CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2751952C2 |
| VECTOR BASED ON ADENO-ASSOCIATED VIRUS FOR THERAPEUTIC DELIVERY TO CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2804953C2 |
| MODIFICATION OF B-CELLS | 2018 |
|
RU2783116C2 |
| ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO CENTRAL NERVOUS SYSTEM | 2014 |
|
RU2692251C2 |
| ADENO-ASSOCIATED VIRUS-MEDIATED GENE TRANSFER INTO THE CENTRAL NERVOUS SYSTEM | 2014 |
|
RU2801511C1 |
| METHODS AND COMPOSITIONS FOR INTENSIFYING ANTI-INFLAMMATORY EFFECTS OF INTERLEUKIN 10 | 2017 |
|
RU2731160C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND-PROMOTER | 2015 |
|
RU2708311C2 |
| METHODS AND COMPOSITIONS FOR DELIVERING THERAPEUTIC PROTEIN | 2019 |
|
RU2818779C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND PROMOTER | 2015 |
|
RU2799573C2 |
